Editas Medicine (EDIT) Competitors

Editas Medicine (NASDAQ:EDIT) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability.

Do insiders and institutionals believe in EDIT or ORGO?

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 1.9% of Editas Medicine shares are held by insiders. Comparatively, 36.9% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more volatility and risk, EDIT or ORGO?

Editas Medicine has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Do analysts rate EDIT or ORGO?

Editas Medicine presently has a consensus target price of $7.00, suggesting a potential upside of 409.09%. Organogenesis has a consensus target price of $5.00, suggesting a potential upside of 32.45%. Given Editas Medicine's higher probable upside, research analysts plainly believe Editas Medicine is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	2 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.07
Organogenesis	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in EDIT or ORGO?

Editas Medicine received 216 more outperform votes than Organogenesis when rated by MarketBeat users. However, 66.44% of users gave Organogenesis an outperform vote while only 53.23% of users gave Editas Medicine an outperform vote.

Company	Underperform	Outperform
Editas Medicine	Outperform Votes 313 53.23%	Underperform Votes 275 46.77%
Organogenesis	Outperform Votes 97 66.44%	Underperform Votes 49 33.56%

Does the media refer more to EDIT or ORGO?

In the previous week, Editas Medicine had 7 more articles in the media than Organogenesis. MarketBeat recorded 13 mentions for Editas Medicine and 6 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.25 beat Editas Medicine's score of 0.22 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, EDIT or ORGO?

Organogenesis has higher revenue and earnings than Editas Medicine. Organogenesis is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$78.12M	1.45	-$153.22M	-$2.56	-0.54
Organogenesis	$433.14M	1.10	$4.95M	-$0.06	-62.92

Is EDIT or ORGO more profitable?

Organogenesis has a net margin of -1.62% compared to Editas Medicine's net margin of -340.96%. Organogenesis' return on equity of -2.69% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-340.96%	-80.13%	-50.99%
Organogenesis	-1.62%	-2.69%	-1.63%

Summary

Organogenesis beats Editas Medicine on 10 of the 18 factors compared between the two stocks.